EO-1606

CAS No. 344457-87-0

EO-1606( —— )

Catalog No. M34588 CAS No. 344457-87-0

EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 686 In Stock
10MG 938 In Stock
25MG 1444 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    EO-1606
  • Note
    Research use only, not for human use.
  • Brief Description
    EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.
  • Description
    EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    p38 MAPK
  • Recptor
    p38 MAPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    344457-87-0
  • Formula Weight
    353.82
  • Molecular Formula
    C21H17ClFNO
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=CC=C(C=C1Cl)NC2=CC=C(F)C=C2C)C=3C=CC=CC3C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • SB 203580

    A specific p38 MAPK inhibitor with IC50 of 0.6 uM; shows selectivity over JNK, p42 MAPK, p90 S6K, p70 S6K, PKA, etc.

  • Losmapimod

    Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.

  • Emprumapimod

    Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.